Comparative Pharmacology
Head-to-head clinical analysis: GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE versus WYAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE versus WYAMINE SULFATE.
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE vs WYAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Pseudoephedrine hydrochloride is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and nasal decongestion. It also has weak beta-adrenergic activity.
Wyamine sulfate (mephentermine sulfate) is a sympathomimetic amine that acts primarily by releasing norepinephrine from presynaptic nerve terminals, with direct alpha- and beta-adrenergic receptor agonist activity. It causes vasoconstriction and positive inotropic effects, increasing cardiac output and blood pressure.
Guaifenesin 400 mg and pseudoephedrine hydrochloride 60 mg orally every 4 to 6 hours as needed, not to exceed 4 doses per 24 hours.
Intramuscular injection: 15-30 mg as a single dose; may repeat in 10-15 minutes if needed. Maximum total dose: 60 mg.
None Documented
None Documented
Guaifenesin: 1 hour (short half-life requiring frequent dosing). Pseudoephedrine: 4-6 hours (prolonged to 16-20 hours with alkaline urine).
Terminal elimination half-life is 6-8 hours in adults with normal renal function (CrCl >90 mL/min).
Guaifenesin: Renal, approximately 60% unchanged and 40% as metabolites. Pseudoephedrine: Renal, 55-75% unchanged, dose-dependent with acidic urine enhancing elimination.
Primarily renal; 90% excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Category A/B
Category C
Sympathomimetic
Sympathomimetic